secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0000950170-24-138767
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene enters $100M ATM equity sale agreement with Jefferies
------------------------------------------------------------

- Entered Open Market Sale Agreement with Jefferies for ATM offering of common shares up to $100M.
- Jefferies receives up to 3% commission; shares sold under prospectus supplement dated Dec 20, 2024.
- Offering not available in Canada and company not obligated to sell any shares.
- Agreement terminable by either party; proceeds for general corporate purposes not specified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024138767/0000950170-24-138767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024138767/engn-20241220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-138767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer